Role of polyglutamates in methotrexate action

Area of Science:

• Pharmacology
• Biochemistry
• Oncology

Background:

• Methotrexate (MTX) is a key chemotherapy agent.
• High-dose MTX (HDMTX) therapy is used for various cancers.
• MTX is metabolized into polyglutamate forms within cells.

Purpose of the Study:

• To investigate the formation, characteristics, and efflux kinetics of MTX polyglutamates.
• To explore the relationship between MTX polyglutamates and HDMTX therapy effectiveness.

Main Methods:

• Analysis of MTX and MTX polyglutamate levels in various cell systems, erythrocytes, and tumor tissues.
• Assessment of concentration- and time-dependency of MTX polyglutamate formation.
• Evaluation of efflux kinetics based on cell type and polyglutamate side chain length.

Main Results:

• MTX polyglutamates are formed in a concentration- and time-dependent manner after MTX and HDMTX treatment.
• Significant intracellular accumulation of MTX and its polyglutamates occurs, exceeding serum levels, especially in erythrocytes with long-term storage.
• High MTX and polyglutamate levels persist in sarcoma tissue for 6-14 days post-HDMTX therapy, with polyglutamate portions ranging from 3% to 68%.

Conclusions:

• MTX polyglutamates exhibit diverse efflux kinetics influenced by cell type and side chain length.
• The formation and accumulation of MTX polyglutamates are significant factors in the pharmacokinetics of MTX and HDMTX therapy.
• A potential correlation exists between MTX polyglutamate formation and the clinical efficacy of HDMTX treatment, highlighting their crucial role.